CSS
GYRE icon

Cubist Systematic Strategies’s Gyre Therapeutics GYRE Stock Holding History

Cubist Systematic Strategies’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-979
Closed -$5.16K – 3572
2023
Q2 		$5.16K Buy
+979
New +$3.51K ﹤0.01% 3305
2021
Q2 		– Sell
-3,651
Closed -$138K – 2977
2021
Q1 		$138K Buy
+3,651
New +$167K ﹤0.01% 2581
2018
Q3 		– Sell
-935
Closed -$82K – 1963
2018
Q2 		$82K Buy
+935
New +$164K ﹤0.01% 1582

Other funds holding GYRE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Cubist Systematic Strategies's GYRE Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Gyre Therapeutics (GYRE) in Q3 2023, closing a stake of 979 shares — an estimated $5.16K sold.

Cubist Systematic Strategies first reported a position in GYRE in Q2 2018 and held it in 3 quarters. The position peaked at $138K in Q1 2021. 31 funds tracked by Wall St. Rank hold GYRE as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Gyre Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 979 Gyre Therapeutics shares in Q3 2023, an estimated $5.16K.
  • Cubist Systematic Strategies first reported a position in Gyre Therapeutics in Q2 2018 and held it in 3 quarters.
  • Cubist Systematic Strategies's Gyre Therapeutics position peaked at $138K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.